Rana Moustafa et al., Health Care Current Reviews 2017, 5:4(Suppl)
DOI: 10.4172/2375-4273-C1-036

THE EFFICACY OF DAPAGLIFLOZIN AS A NOVEL ORAL ANTIHYPERGLYCEMIC DRUG IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS IN QATAR

Rana Moustafa[a], **Zainab Malik**[a] and **Dina Al Tayeb**[a]
[a]Hamad Medical Corporation, Qatar

Dapagliflozin is the second FDA approved agent in a new class of oral antihyperglycemic drugs, the sodium-glucose cotransporter 2 (SGLT2) inhibitors with innovative mechanisms of action. Managing diabetes mellitus (DM) with effective and tolerable oral agents will eventually decrease the devastating complications associated with the uncontrolled DM and ultimately improve the quality of life. This study aimed to assess the effectiveness of new oral antihyperglycemic drug Dapagliflozin in the treatment of type 2 DM as monotherapy or combination with other hypoglycemic agents in term of reduction in HbA1c and fasting blood glucose at 6, 9 and 12 months. In this retrospective study, all patients treated with Dapagliflozin in Hamad Medical Corporation (HMC) since its introduction as non-formulary medication on 1 April 2013 until 30th of April 2015 were included. Data regarding prescribed drugs were obtained from the computerized pharmacy system. Demographic information and laboratory results of patients have been achieved from the patient's electronic system (CERNER). Eighty-one patients were identified to receive Dapagliflozin during the study period, 71 % of them were males, and 100 % were Qataris with mean age 57 ± 9 years and mean A1C baseline 9 ± 1.4 %. Of note, all patients were receiving Dapagliflozin as add on therapy in combination with the standard therapy. Administration of Dapagliflozin as add-on therapy was found to decrease A1C significantly after 6 months by 0.8 (P=0.006), and after 12 months by 1.5 (P=0.062). Moreover, found to reduce the fasting blood significantly at 6 months and 9 months (P= 0.001, P=0.03 respectively). However, the coadministered antidiabetic medication did not influence the reduction in A1C or FBG. Dapagliflozin significantly reduced HbA1c level and the fasting blood glucose of type 2 diabetic patients in combination of other OHA or insulin within 6 to 12 months of treatment.

Biography

Rana Moustafa is a Clinical Pharmacist at Hamad General Hospital, an entity of Hamad Medical Corporation. She received her Bachelor's degree in Pharmacy in 2007 from Egypt. In 2012, she completed her Master's degree in Clinical Pharmacy from Queen's University of Belfast (UK). She joined the corporation in 2008 as a Pharmacist and in 2012. She joined the Clinical Pharmacy team, to provide service in medical wards, and is engaged in many researches in the clinical field and provides continuous education to patients, patient's family and medical staff.

rahmed@hamad.qa

Notes: